Ascelia Pharma är ett läkemedelsbolag. Bolaget är specialiserat inom utveckling av särläkemedel inom onkologi (cancer). Bolaget utvecklar diverse läkemedelskandidater, där störst användning återfinns inom behandling av cancer som drabbat lever och magsäck. Bolaget grundades år 2000 och har huvudkontor i Malmö, Sverige, men är verksamt på en global marknad.
Ascelia Pharma is expected to release its Q2 2026 results on 20 August 2026. The following day at 10:00, CEO Magnus Corfitzen will present the results and provide an update on the company's latest developments in a live online event.
* Type A meeting with the FDA scheduled for September 9 * Implementing cost-saving measures * Conf call at 10am CET Recent and upcoming relevant events Following the July 2, 2026 Complete Response Letter for Orviglance, which cited concerns over the ...
Välkommen med i Inderes community!
Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!
Inderes användarkonto
Ger dig möjlighet att följa bolag och beställa notifikationer
Tillgång till analytikerkommentarer och rekommendationer
Tillgång till vårt aktiescreeningsverktyg och andra populära verktyg
Ascelia Pharma announced today that the FDA has scheduled a Type A meeting for 9 September 2026 to discuss the Complete Response Letter issued in early July. The company has submitted a briefing package addressing each of the topics raised by the agency.
Following the FDA's Complete Response Letter for Orviglance and the subsequent publication of the redacted letter, we set out what the current share price implies, the scenarios we see into the Type A meeting, and our reading of the clinical issue at the centre of the case.
The FDA's Complete Response Letter (CRL) for Orviglance (NDA 220544) is now publicly accessible in redacted form through the FDA's openFDA transparency database. The letter's specifics raise the odds of a more demanding path to approval than previously indicated.
* CRL questions SPARKLE endpoint analysis; re-read rejected *Ascelia disputes both points; expresses confidence * Type A meeting next; outcomes range widely The CRL's stated grounds In the CRL (Complete Response Letter), the FDA states that SPARKLE failed...
Ascelia Pharma provided a follow-up update yesterday, July 12, on the Complete Response Letter received on July 3. This is the first substantive detail the company has disclosed on the nature of the FDA's clinical concerns since the CRL, and it meaningfully narrows, though does not close, the range of scenarios we flagged in our July 3 note.
